References
- Asara Y, Marchal JA, Carrasco E, et al (2013). Cadmium modifies the cell cycle and apoptotic profiles of human breast cancer cells treated with 5-fluorouracil. Int J Mol Sci, 14, 16600-16. https://doi.org/10.3390/ijms140816600
- Bermudez Y, Yang H, Cheng JQ, et al (2008). Pyk2/ERK 1/2 mediate Sp1- and c-myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors, 26, 1-11. https://doi.org/10.1080/08977190802001389
- Bresalier RS, Sandler RS, Quan H, et al (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 352, 1092-102. https://doi.org/10.1056/NEJMoa050493
-
Cervello M, Giannitrapani L, La Rosa M, et al (2004). Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspasedependent cleavage of
$\beta$ -catenin and inhibition ofb$\beta$ -cateninmediated transactivation. Int J Mol Med, 13, 741-8. - Charames G S, Bapat B (2006) Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol, 28, 543-9.
- Chen S, Qiong Y, Gardner DG, et al (2006). A role for p38 mitogenactivated protein kinase and c-myc in endothelindependent rat aortic smooth muscle cell proliferation. Hypertension, 47, 252-8. https://doi.org/10.1161/01.HYP.0000198424.93598.6b
- Cronin-Fenton DP, Pedersen L, Lash TL, et al (2010). Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res, 12, 15.
- Cusimano A, Fodera D, D'Alessandro N, et al (2007). Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Therapy, 6, 1461-8.
- Daksis JI, Lu RY, Facchini LM, et al (1994). Myc induces cyclin D1 expression in the absence of denovo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene, 9, 3635-45.
- Dong JY, Wang Q, Liang QD, et al (2013). Construction and identification of recombinant adenovirus with COX-2- shRNA. Chin J Biologicals, 26, 1072-7.
- Fodera D, D'Alessandro N, Cusimano A, et al (2004). Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci, 1028, 440-9. https://doi.org/10.1196/annals.1322.052
- George C (1999). Mechanisms of apoptosis by c-myc. Oncogene, 18, 2967-87. https://doi.org/10.1038/sj.onc.1202727
- Half E, Tang XM, Gwyn K, et al (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res, 62, 1676-81.
- Han G, Gang W, Yan B, et al (2012). C-myc overexpression promotes osteosarcoma cell invasion via activation of MEKERK pathway. Oncol Res, 20, 149-56. https://doi.org/10.3727/096504012X13522227232237
- Harris RE, Beebe-Donk J, Doss H, et al (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep, 13, 559-83.
- He TC, Zhou S, Luis T, et al (1998). A simplified system for generating recombinant adenoviruses. Medical Sciences Proc. Natl Acad Sci. 95, 2509-14 https://doi.org/10.1073/pnas.95.5.2509
- Hochegger H, Takeda S, Hunt T, et al (2008). Cyclin-dependent kinases and cell cycle transitions: does one fit all? Nat Rev Mol Cell Biol, 9, 910-6.
- Hoffman B and Liebermann DA (2008). Apoptotic signaling by c-MYC. Oncogene, 27, 6462-72. https://doi.org/10.1038/onc.2008.312
- Janghorban M, Farrell AS, Allen-Petersen BL, et al (2014). Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA, 111, 9157-62. https://doi.org/10.1073/pnas.1317630111
- Jovanovic M, Stefanoska I, Radojcic L, et al (2010). Interleukin-8 (CXCL8) stimulates trophoblast cell migration and invasion by increasing levels of matrix metalloproteinase (MMP) 2 and MMP9 and integrins alpha5 and beta1. Reproduction. 139, 789-98. https://doi.org/10.1530/REP-09-0341
- Holmes MD, Chen WY, Schnitt SJ, et al (2011). COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat, 130, 657-62. https://doi.org/10.1007/s10549-011-1651-7
- Ferguson RD, Novosyadlyy R, Fierz Y, et al (2012). Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res, 14, 8.
- Komatsu K, Buchanan FG, Katkuri S, et al (2005). Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology, 129, 577-90. https://doi.org/10.1016/j.gastro.2005.06.003
- Lin MT, Lee RC, Yang PC, et al (2001). Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem, 276, 48997-9002. https://doi.org/10.1074/jbc.M107829200
- Llovet JM, Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatol, 48, 1312-27. https://doi.org/10.1002/hep.22506
- Murata H, Kawano S, Tsuji S, et al (1999). Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Amer J Gastroenterol, 94, 451-5. https://doi.org/10.1111/j.1572-0241.1999.876_e.x
- Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108 https://doi.org/10.3322/canjclin.55.2.74
- Patel VA, Dunn MJ, Sorokin, et al (2002). Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem, 277, 38915-20. https://doi.org/10.1074/jbc.M206855200
- Schutze N (2004). siRNA technology. Mol Cell Endocrinol, 213, 115-9. https://doi.org/10.1016/j.mce.2003.10.078
- Shalaby MA, Nounou HA, Alanazi MS, et al (2014). Associations between single nucleotide polymorphisms of COX-2 and MMP-2 genes and colorectal cancer susceptibility in the Saudi population. Asian Pac J Cancer Prev, 15, 4989-94. https://doi.org/10.7314/APJCP.2014.15.12.4989
- Shirahama T, Arima J, Akiba S, et al (2001). Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92, 188-93. https://doi.org/10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W
- Siegfried JM, Gubish CT, Rothstein ME, et al (2007). Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol, 72, 769-79. https://doi.org/10.1124/mol.107.034215
- Singh B, Berry JA, Shoher A, et al (2006). COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol, 26, 1393-9.
- Singh B, Cook KR, Vincent L, et al (2011). Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res, 168, 39-49. https://doi.org/10.1016/j.jss.2010.03.003
- Sobolewski C, Cerella C, Dicato M, et al (2010). The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol, 2010, 215158 (21 pages).
- Song D, Miao Cui M, Zhao G, et al (2014). Pathway-based analysis of breast cancer. Am J Transl Res, 6, 302-11.
- Strillaeeit A, Griffoni C, Spiral E, et al (2006). RNA interference as a key to knockdown overexpressed cyclooxygenase-2 in tumor cells. Br J of Cancer, 94, 1300-10. https://doi.org/10.1038/sj.bjc.6603094
- Su B, Chen S (2009). Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. Bioorg Med Chem Lett, 19, 6733-5. https://doi.org/10.1016/j.bmcl.2009.09.109
- Tai WT, Cheng AL, Shiau CW, et al (2011). Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol, 55, 1041-8. https://doi.org/10.1016/j.jhep.2011.01.047
- Xia JJ, Pei LB, Zhuang JP, et al (2010). Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res, 38, 1294-304. https://doi.org/10.1177/147323001003800411
- Yamanaka Y, Shiraki K, Inoue T, et al (2006). COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAILinduced apoptosis. Int J Mol Med, 18, 41-7.
Cited by
- Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability vol.11, pp.1, 2016, https://doi.org/10.1186/s13020-016-0116-7
- Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1103
- Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway vol.35, pp.6, 2016, https://doi.org/10.3892/or.2016.4764